Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Long Term Safety and Efficacy of Gamma Knife Thalamotomy for Essential Tremor: A Single Center Study
Movement Disorders
Movement Disorders Posters (7:00 AM-5:00 PM)
019

To evaluate the long term safety and efficacy of GK thalamotomy in patients with medically refractory ET who are not considered good candidates for Deep Brain Stimulation.

Gamma Knife (GK) thalamotomy is used as a surgical treatment for patients with medically refractory Essential Tremor (ET) yet there is paucity of studies on its long term safety and efficacy.

All patients with medically refractory ET who underwent GK thalamotomy at our center were included. Based on retrospective chart review, tremor severity and improvement was assessed using Clinical Global Impression Severity (CGI-S) and Improvement (CGI-I) scales at baseline (before GK procedure) and at three visits after the procedure. With a phone interview, activities of daily living were scored on Essential Tremor Rating Assessment Scale (TETRAS). Safety was assessed based on chart review of reported GK complications.

Forty seven patients were included, age 74 ± 14.38, 66% were male. Tremor severity improved from CGI-S 3.91 ± 0.75 at baseline to 2.81 ± 0.97 (p< 0.07) at 6.03 ± 1.74 months, 2.64 ± 0.79 (p <0.0060) at 11.41 ± 1.97 months, and 2.22 ± 0.67 (p <0.0060)  at 36.78 ± 31.89 months. Patients reported tremor to be ‘much improved’ CGI-I 1.95 ± 1.13 on their most recent visit. Twenty four patients were available for phone interview and reported improvement in their ADL’s based on TETRAS from 3.5 ± 0.72 (moderate to severe disability) to 2.04 ± 1.33 (mild) (p<0.001) at 32.92 ± 40.14 months. Complications were generally mild. Three patients had evidence of radiation necrosis on imaging (two developed ataxia, one had hemiparesis which responded to steroids).

In this large single center study, GK was found to provide sustained long term efficacy and safety for patients with medically refractory essential tremor. GK can be considered for patients who are not candidates for DBS.

Authors/Disclosures
Marisa McGhee, MD (Atrium Wake Forest Baptist Hospital)
PRESENTER
Dr. McGhee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. McGhee has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen.
No disclosure on file
Mustafa S. Siddiqui, MD, FÂé¶¹´«Ã½Ó³»­ Dr. Siddiqui has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Boston Scientific Neuromodulation. Dr. Siddiqui has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. The institution of Dr. Siddiqui has received research support from Boston Scientific Neuromodulation. The institution of Dr. Siddiqui has received research support from Abbvie. The institution of Dr. Siddiqui has received research support from National Institute of Health .